Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer

Back

Galina Mal

Galina Mal

Kursk State Medical University, Kursk, Russia.

Title: Specific of a drug response of statins in patients with ischemic heart disease based on polymorphism of gene-regulators of lipid metabolism.

Biography

Biography: Galina Mal

Abstract

Objective: To assess the degree of expression of the drug response in patients with ischemic heart disease depending of polymorphic variants of lipid metabolism gene-regulators.

Methods: Assessment of lipid composition of blood, molecular genetic methods.

Results: Polymorphic variants of lipid metabolism control genes are also associated with the risk of developing ischemic heart disease.  The risk of developing ischemic heart disease increases with the carriers of the genes LPA (rs10455872) A>G, APOC1 (rs445925) G>A, APOE (rs7412) C>T.

Polymorphic variants of gene-regulators of lipid metabolism influenced the hypolipidemic effect of rosuvastatin in patients with ischemic heart disease.  In patients with polymorphic variants of LPA (rs10455872) A>G, there was a weakening of the cholesterin-lowering effect in homozygous G/G and heterozygous G/A compared to homozygous A/A. In carriers of polymorphic variants APOC1 (rs445925) G>A  the greatest drug response of rosuvastatin in homozigous A/A. A similar trend in the formation of drug metabolism of rosuvastatin was observed in carriers of polymorphic variants APOE (rs7412) C>T: the greatest decrease in total cholesterol was registered in homozygous T/T.

Conclusions: the reduction of total cholesterol was more pronounced in patients whose genotype did not have variant allels of these polymorphisms. 

The influence of polymorphic variants of lipid metabolism gene regulators affects the degree of expression of the drug response of statins in patients with ischemic heart disease.